about
Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patientsHigh plasma heparin cofactor II activity protects from restenosis after femoropopliteal stentingFrequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions.Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation.An experimental model to study isolated effects of thrombin in vivo.Dabigatran: patient management in specific clinical settings.High D-dimer levels are associated with poor prognosis in cancer patientsCardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis StudyFibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause.Tissue factor exposing microparticles in inflammatory bowel disease.Leptin induces endothelin-1 in endothelial cells in vitro.Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications.FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors.Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow.Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression?von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study.The fibrinogen -148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo.Vitamin C inhibits NO-induced stabilization of HIF-1alpha in HUVECs.Platelet dysfunction in outpatients with left ventricular assist devices.Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers.Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.The course of anticardiolipin antibody levels under immunoadsorption therapy.The formation of platelet-leukocyte aggregates varies during the menstrual cycle.Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.Association of periprocedural neurological deficit in carotid stenting with increased anticardiolipin antibodies.Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.Superficial thrombophlebitis and risk for recurrent venous thromboembolism.Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion.Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.Extended monitoring of hemostatic activation after varicose vein surgery under general anesthesia.Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers.The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.Homozygous antithrombin deficiency type II causing neonatal thrombosis.The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism.A patient with sudden abdominal pain 10 years after successful renal transplantation.Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin.
P50
Q28221281-17BBFE8F-E1A3-49E0-B64D-C9F939B58504Q28293256-A745AB77-ADAE-47E2-B598-7B9AEFDACEE2Q33341892-D291198E-3E54-4267-B995-3C9B79255794Q33346515-EC06E3DA-1714-447D-BD96-532B44C61DAEQ33392027-1AE352FC-85DC-4DBB-B8AD-D2A6B857C23FQ34196100-BD7B333A-1322-4A13-9853-B9E099A680A7Q36133005-2806663A-0488-4E4A-84F4-8B8A4AE3503BQ36303250-DD68848C-E44B-4789-92E2-D5D205B6063AQ37060686-A8B71C32-070A-42D4-9122-05BC88F2EB3DQ37620112-1CB303F9-3531-41F4-93F7-99A72FBABBF0Q38019249-466A341B-B027-4CCF-A64E-65F771BBD97EQ38290517-6E8742D8-5139-4585-A504-11D46581716DQ38865538-12D16222-7E25-483B-818F-F4D97E07A37FQ39742340-C8EEE8F8-97E0-45CC-B1A1-3B2B7FE03CB3Q39962890-EDDBD69E-A669-442D-BEA7-6E291F46DD3CQ40131849-CD99AC8F-03C0-4757-9C3E-B008BDB17D0DQ40417005-EE01CA0F-579D-4667-91B4-2F1CA8BC5FF2Q40594032-C5FC6F8E-C8EF-4586-B59E-1B2B12AB2249Q41980530-6DB51A56-369A-4F0D-9C71-C67D29BA2BA7Q42508383-CF85353B-B84B-481E-87CA-815B5C49646EQ43104701-2B848A02-AA80-4FAD-930A-CD0229AF86E5Q44855747-093FE875-8AB5-411B-8FEF-E2B5E0669C5FQ45368928-1D02A534-5D5F-451C-A3A4-572EA6BE38C0Q45945704-7E57D147-9DAD-40B3-A807-E4EB88BCCA37Q46675383-8D648C9A-9443-4F8B-89A6-63C27A5B1321Q46820395-3CC766A5-C759-454E-A69D-145B1F7A8E37Q47247982-3D224E49-1BDD-4749-AFB0-E964DDCA5B25Q47327067-4C1AA3C1-8317-426C-BAE8-79668E170DAFQ47621633-DFF6B960-393F-4719-A27D-D6CCB237504CQ47821600-2D8072F8-D51C-46F0-89AE-1B92C62D82D8Q48006347-021A3823-7701-4DF6-880F-4AB453FBA02DQ48276514-7194A0C9-F4AD-4578-9544-DEFC24682DB2Q48502655-C8EBCFF9-8ED1-45E6-9EAF-B22C22291C63Q48697259-8C778F20-FCD7-4CAF-854D-06BA9B0F2BDCQ50109567-16B7F814-9CCA-436A-BDFA-804A1AA5A4FFQ50112659-18F2BCA4-22AC-4DA4-B14F-81989EBE8AF2Q50154037-E081770B-F0B1-47E2-ACA5-12A365580E14Q50331345-075FF285-08F8-4193-A119-487FB85AF044Q50762182-613C9E4A-43A1-4F27-B96B-AA9D4EB107EAQ50889032-1F9910D5-06D3-40A2-ABD7-572F90B93C1D
P50
name
Peter Quehenberger
@ast
Peter Quehenberger
@en
Peter Quehenberger
@es
Peter Quehenberger
@nl
type
label
Peter Quehenberger
@ast
Peter Quehenberger
@en
Peter Quehenberger
@es
Peter Quehenberger
@nl
prefLabel
Peter Quehenberger
@ast
Peter Quehenberger
@en
Peter Quehenberger
@es
Peter Quehenberger
@nl